Marker Therapeutics, Inc.
MRKRNASDAQHealthcare● Active
$1.46
+$0.04(+2.82%)
Market Cap$15764696
P/E Ratio—
52W High$4.07
52W Low$0.81
Marker Therapeutics, Inc. (MRKR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MRKR · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.01B | $0.01B | $0.01B | $0.00B |
| Gross Profit | $0.00B | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| Gross Margin %(computed) | — | -104.33% | -214.60% | -240.64% | -154.70% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.03B |
| G&A Expenses | $0.00B | $0.00B | $0.01B | $0.01B | $0.00B |
| Total Operating Expenses | $0.01B | $0.00B | $0.01B | $0.01B | $0.04B |
| Operating Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.04B) |
| Operating Margin %(computed) | — | -168.69% | -440.37% | -563.28% | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.04B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.03B) | ($0.04B) |
| Net Margin %(computed) | — | -162.82% | -248.76% | -851.87% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.79 | $-1.19 | $-1.93 | $-3.58 | $-5.47 |
| Wtd Avg Shares | 0.02B | 0.01B | 0.01B | 0.01B | 0.01B |
| EBITDA | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.04B) |
| EBITDA Margin %(computed) | — | -168.69% | -356.14% | -483.90% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Marker Therapeutics, Inc. data
About Marker Therapeutics, Inc. (MRKR) Income Statement
Marker Therapeutics, Inc. (MRKR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MRKR reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
MRKR · 4 questionsMarker Therapeutics, Inc. (MRKR) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
MRKR revenueMRKR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09